List of Vuity drug patents

Vuity is owned by Abbvie Inc.

Vuity contains Pilocarpine Hydrochloride.

Vuity has a total of 2 drug patents out of which 0 drug patents have expired.

Vuity was authorised for market use on 28 October, 2021.

Vuity is available in solution;ophthalmic dosage forms.

Vuity can be used as use of vuity for the treatment of presbyopia in adults.

The generics of Vuity are possible to be released after 24 April, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610518 ABBVIE INC Presbyopia treatments
Apr, 2039

(16 years from now)

US11285134 ABBVIE INC Presbyopia treatments
Apr, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Oct 28, 2024

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 28 October, 2021

Treatment: Use of vuity for the treatment of presbyopia in adults

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in